Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRONARTO: tiotropium + olodaterol via Respimat versus placebo in moderate to severe COPD stratified by peak inspiratory flow rate
2019-001719-21Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tiotropium + olodaterol, tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline in FEV1 AUC0-3h. Started Nov 2019; status: completed.
02
Drugs
tiotropium + olodateroltiotropiumolodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2019-001719-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001719-21.